In this article, the authors report the 10-year final results of the NOBLE trial comparing percutaneous coronary intervention (PCI) with newer generation drug–eluting stents vs coronary artery bypass grafting (CABG) for unprotected left main coronary artery disease without additional complex lesions. In the intention–to–treat analysis of 1,184 patients, 10–year all-cause mortality did not differ between PCI and CABG (23 percent vs 25 percent; hazard ratio [HR] 0.93, 95 percent confidence interval [CI] 0.74 to 1.18). No mortality difference was observed in landmark analyses from zero to five years or from five to 10 years, nor across SYNTAX score strata. Importantly, the current analysis did not involve secondary endpoints, including myocardial infarction, stroke, repeat revascularization, and cause of death.
1 Comment
The 10-year results of the NOBLE trial concluded that PCI is “equally as safe as CABG” for unprotected left main stenosis. However, a closer look at the baseline characteristics and study design reveals significant biases that undermine this conclusion.
1. Critical Baseline Imbalance There is a notable disparity in clinical gravity at enrollment. The CABG group included significantly more symptomatic patients (NYHA Class III/IV: 24% in CABG vs. 18% in PCI; p=0.012). Furthermore, the CABG arm was assigned a higher number of lesions requiring treatment (p<0.0001). These data suggest that the CABG group faced a "double handicap"—sicker patients and more extensive disease—yet achieved survival parity, which speaks more to the robustness of CABG than the equivalence of PCI.
2. Misleading Confounding of ACS and CCS Merging Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS) into a single "left main" category is clinically unsound. In the ACS subgroup, CABG patients suffered a median treatment delay of 6 days compared to only 1 day for PCI. This logistical failure likely drove the abnormally high 10-year mortality in the ACS-CABG arm (31%), which skewed the overall ITT results.
3. Misleading Conclusion The study’s title and interpretation are misleading. By masking the superior outcomes of CABG in stable, complex disease with the poor outcomes of "delayed" CABG in ACS, the authors have created a false sense of parity. Future guidelines must demand stratified data to avoid over-simplifying the complex reality of heart team decision-making.
Respectfully,